RAD51-IN-1

Cat. No.:	HY-122705
CAS No.:	2101739-18-6
Molecular Formula:	$C_{22}H_{16}ClN_3O$
Molecular Weight:	373.83
Target:	RAD51
Pathway:	Cell Cycle/DNA Damage
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 62.5 mg/mL (167.19 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.6750 mL	13.3751 mL	26.7501 mL
	5 mM	0.5350 mL	2.6750 mL	5.3500 mL
	10 mM	0.2675 mL	1.3375 mL	2.6750 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (5.56 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

RAD51-IN-1, a derivative of B02, is a potent inhibitor of RAD51. RAD51-IN-1 can be used for cancer research[1].

In Vitro

RAD51 is a vital component of the homologous recombination DNA repair pathway and is overexpressed in drug-resistant cancers, including aggressive triple-negative breast cancer (TNBC)[1].

RAD51-IN-1 (10 μM) decreases the ratio of RAD51 positive cells/cH2AX positive cells in MDA-MB-231 cell exposure to 6 Gy irradiation[1].

RAD51-IN-1 (10 μM) significantly inhibits DNA damage induced RAD51 foci formation with 6 Gy irradiation[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Ambber Ward, et al. Quinazolinone derivatives as inhibitors of homologous recombinase RAD51. Bioorg Med Chem Lett. 2017 Jul 15;27(14):3096-3100.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA